clinical trial

[Abcuro, Inc.] Abcuro, Inc. and ImaginAb shared initial results of a study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis, an autoimmune disease in which cytotoxic CD8+ T cells chronically attack muscle cells, leading to progressive weakness and severe disability.

[Flinders University] A blood test to help guide the treatment of oesophageal, stomach and bowel cancers will be evaluated in a new Flinders University trial set to get underway. The blood test is currently offered under the brand name COLVERA® in the US as a tool to aid in the detection of cancer relapse after treatment.

[Clinical Cancer Research] Patient tumor organoids (PTO) were fabricated using unsorted tumor cells with and without enrichment with patient matched immune components derived from peripheral blood leukocytes, spleen, or lymph nodes.

[Cynata Therapeutics Limited (BioSpace)] Cynata Therapeutics Limited announced that it has received approval by the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ MSC product in patients with diabetic foot ulcers.

[Axcella, Inc.] Axcella, announced that it has activated initial clinical sites and patient screening for its global Phase II clinical trial of AXA1665, the company’s multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy.

[Histogen Inc.] Histogen Inc. has announced the initiation of its Phase I/II clinical trial of HST 003 to evaluate the safety and efficacy of human ECM implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.